Tourmaline Bio, Inc. - Common stock, par value $0.0001 per share (TRML)

131 filings reported holding TRML - Tourmaline Bio, Inc. - Common stock, par value $0.0001 per share as of Q2 2025.
Tourmaline Bio, Inc. - Common stock, par value $0.0001 per share (TRML) has 107 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 24.1M shares of 25.7M outstanding shares and own 93.75% of the company stock.
Largest 10 shareholders include Avoro Capital Advisors LLC (2.56M shares), RA CAPITAL MANAGEMENT, L.P. (2.54M shares), QVT Financial LP (2.15M shares), BlackRock, Inc. (1.63M shares), TCG Crossover Management, LLC (1.48M shares), Pfizer Inc (1.27M shares), VANGUARD GROUP INC (1.21M shares), Blue Owl Capital Holdings LP (997K shares), Octagon Capital Advisors LP (905K shares), and QIMING U.S. VENTURES MANAGEMENT, LLC (742K shares).
This table shows the top 107 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.